Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
Earnings Data
Report Date
Feb 10, 2026Before Open (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
1.25Last Year’s EPS
1.19Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in organic revenue, adjusted EPS, and gross margin expansion. Plasma and Blood Management Technologies showed robust performance, reinforcing strong cash generation and increased free cash flow guidance. However, overall revenue showed a decline due to portfolio transitions, and Interventional Technologies faced challenges. Despite these lowlights, the call maintained a positive outlook on future growth and profitability.Company Guidance
Growth in Organic Revenue
Excluding portfolio transitions, organic growth excluding CSL was 9% in the quarter and 11% year-to-date.
Adjusted EPS Increase
Adjusted EPS increased 13% in the quarter and 11% year-to-date, reaching $1.27 and $2.36, respectively.
Plasma Revenue Growth
Organic revenue for Plasma grew 19% in the quarter and 23% year-to-date, driven by share gains and innovation.
Record Gross Margin Expansion
Adjusted gross margin reached 60.5% in the quarter and 60.6% year-to-date, driven by technology adoption and favorable product mix.
Strong Operating Cash Flow
Operating cash flow was $111 million in the quarter, up 128% year-over-year, and $129 million year-to-date, indicating strong cash generation.
Increased Free Cash Flow Guidance
Full year free cash flow guidance raised to $170 million to $210 million, emphasizing strong cash discipline and capital stewardship.
Blood Management Technologies Growth
Blood Management Technologies revenue was up 12% in the quarter and 13% year-to-date, supported by hemostasis management and transfusion management.
HAE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HAE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $50.72 | $67.11 | +32.31% |
Aug 07, 2025 | $75.77 | $55.63 | -26.58% |
May 08, 2025 | $64.25 | $68.01 | +5.85% |
Feb 06, 2025 | $71.24 | $62.99 | -11.58% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Haemonetics Corp. (HAE) report earnings?
Haemonetics Corp. (HAE) is schdueled to report earning on Feb 10, 2026, Before Open (Confirmed).
What is Haemonetics Corp. (HAE) earnings time?
Haemonetics Corp. (HAE) earnings time is at Feb 10, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HAE EPS forecast?
HAE EPS forecast for the fiscal quarter 2026 (Q3) is 1.25.